Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 76-84

  Pers, Yves Marie ^a   Fortunet, Clémentine ^b   Constant, Elodie ^c   Lambert, Joseph ^d   Godfrin Valnet, Marie ^e   De Jong, Audrey ^f   Mercier, Grégoire ^f   Prades, Béatrice Pallot ^c   Wendling, Daniel ^e   Gaudin, Philippe ^d   Jorgensen, Christian ^a   Marotte, Hubert ^c   Maillefert, Jean Francis ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

C reactive protein; Cardiovascular disease; Predictors of response; Rheumatoid arthritis; Tocilizumab; Young age

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PREDNISONE; STEROID; TOCILIZUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DAS28; DRUG EFFICACY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASE; PREDICTORS OF RESPONSE; RHEUMATOID ARTHRITIS; TOCILIZUMAB; YOUNG AGE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890957085     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket301     Document Type: Article

References (33)

1. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40.
2. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
3. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
4. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
5. Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
6. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
7. EMA. RoActemra (tocilizumab). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf (15 March 2012, date last accessed).
8. Chatzidionysiou K, Lie E, Nasonov E et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
9. Alessandri C, Bombardieri M, Papa N et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFa therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
10. Bobbio-Pallavicini F, Caporali R, Alpini C et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Pham T, Claudepierre P, Constantin A et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010;77(Suppl 1):S3-100.
13. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
14. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
15. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
16. Burmester GR, Feist E, Kellner H et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.
17. Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int 2010;30:1041-8.
18. Nakashima Y, Kondo M, Harada H et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20:343-52.
19. Takeuchi T, Tanaka Y, Amano K et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011;50:1908-15.
20. Wakabayashi H, Oka H, Nishioka Y et al. Do biologicsnaive patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol 2011;29:314-7.
21. Yamanaka H, Tanaka Y, Inoue E et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011;21:122-33.
22. Bykerk VP, Ostor AJ, Alvaro-Gracia J et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4.
23. Leffers HC, Ostergaard M, Glintborg B et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216-22.
24. Hyrich KL, Watson KD, Silman AJ et al. Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
25. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009;23:111-24.
26. Bathon JM, Fleischmann RM, van der Heijde D et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006;33:234-43.
27. Tanaka T, Kishimoto T. Immunotherapeutic implication of IL-6 blockade. Immunotherapy 2012;4:87-105.
28. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008;371:998-1006.
29. Kaneko A, Kida D, Saito K et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 2012;32:3631-7.
30. Kojima T, Yabe Y, Kaneko A et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 2012, PMID:23099471. Epub 26 October 2013.
31. Mariette X, Gottenberg JE, Ravaud P et al. Registries in rheumatoid arthritis and autoimmune diseases: data fromthe French registries. Rheumatology 2011;50:222-9.
32. Nishimoto N, Miyasaka N, Yamamoto K et al. Longterm safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
33. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2012;72:43-50.